Not an actual patient.

CONSISTENT, RELIABLE, AND LONG-ACTING T SUPPRESSION ENABLED BY A PROPRIETARY DELIVERY SYSTEM

Unique in situ polymeric extended-release delivery system enables sustained, controlled release of leuprolide acetate as it safely biodegrades²

In Situ Polymeric Gel Extended-Release Delivery Technology³

Drug

leuprolide acetate

Biodegradable copolymer

PLG copolymer

Biocompatible liquid carrier

N-methyl-2-pyrrolidone (NMP)

PLG COPOLYMER SOLIDIFIES IN THE BODY DUE TO EXCHANGE OF NMP AND WATER IN TISSUE FLUID AND FORMS A SOLID IN SITU²

After injection, ELIGARD solidifies into a solid, pea-sized pearl. Let your patients know they may feel a tiny bump immediately after injection. The bump reduces in size over time²

ELIGARD being injected into SC tissue and solidifying in situ.

ELIGARD in situ, slowly biodegrading over the dosing period.

Designed for treatment continuity

For patients managing busy schedules, multiple medications, or long periods between visits, ELIGARD is designed to provide consistent treatment throughout the selected dosing interval.^2,3

Long-acting treatment intervals up to 6 months

Sustained delivery throughout the dosing period

Designed to support treatment continuity between visits

Healthcare professional administration helps reduce reliance on daily adherence

Reliable delivery throughout the dosing period allows for more control and confidence throughout treatment

THE ELIGARD PRE-CONNECTED SYRINGE SYSTEM (EPSS) PROMOTES EFFICIENCY WITH JUST ONE CLICK³

Preparation and administration

Prepare

If refrigerated, allow the product to reach room temperature (59-86 °F) before using

Mix

Thoroughly mix ELIGARD by pushing the liquid to powder back and forth for 60 cycles between syringes to obtain a uniform suspension

Administer

Inject ELIGARD at a 90° angle into subcutaneous tissue

Ensuring the proper injection angle enables accurate extended-release delivery

SINCE ELIGARD IS NOT A COMPOUNDED PRODUCT, USP 800 GUIDELINES DO NOT APPLY TO THE MIXING AND ADMINISTRATION⁴

Helpful videos, guides, and training sessions can help you with ELIGARD mixing & administration

MIXING & ADMINISTRATION VIDEO

MIXING & ADMINISTRATION GUIDE

JOIN OUR WEEKLY VIRTUAL MIXING & ADMINISTRATION TRAINING SESSIONS

Virtual training sessions include a demonstration of the mixing and administration of ELIGARD. The clinical trainer will answer any questions you may have.

ELIGARD Can be left at room temperature for up to 8 weeks (56 days) prior to mixing³

Storing ELIGARD

ELIGARD is a refrigerated product and should be stored at 2 °C to 8 °C (36-45 °F) but can be left at room temperature for up to 8 weeks (56 days) prior to mixing and administration³

30-minute administration time limit

If the product is NOT administered within 30 minutes of mixing, it must be discarded³

ELIGARD cannot be re-refrigerated if it has already been mixed⁵

The flexibility in eligard storage offers more advantages for your practice

Get comprehensive support for your practice

LHRH, luteinizing hormone-releasing hormone; PLG, poly(lactic-co-glycolic acid); SC, subcutaneous; T, testosterone.

References: 1. Data on file. IQVIA data, Jan 2025-June 2026. Tolmar, Inc.; 2026. 2. Sartor O. Eligard^®: a new form of treatment for prostate cancer. Eur Urol Open Sci. 2006;5(18):P905-P910. 3. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2026. 4. Data on file. Tolmar, Inc.; 2024. 5. Data on file. Tolmar, Inc.; 2024.

Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD^® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice. Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, and erythema multiforme, occurred in patients receiving ELIGARD. Monitor for and advise patients of the signs and symptoms of SCARs. May cause fetal harm.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

Please see full Prescribing Information for ELIGARD.

CONSISTENT, RELIABLE, AND LONG-ACTING T SUPPRESSION ENABLED BY A PROPRIETARY DELIVERY SYSTEM

Unique in situ polymeric extended-release delivery system enables sustained, controlled release of leuprolide acetate as it safely biodegrades2

In Situ Polymeric Gel Extended-Release Delivery Technology3